Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00512317 · ClinicalTrials.gov registry record · Phase 2

Open-label Extension to Protocol 1042-0600

A Phase 2 study, sponsored by Marinus Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
123
Enrollment target

NCT00512317 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 123 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00512317, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
123 participants
Enrollment target

Study Summary

To allow open-label extension to patients who have completed Protocol 1042-0600.

Interventions

  • DRUG ganaxolone

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2007-06
Est. Completion 2013-09
Phase Phase 2

Sponsor

Marinus Pharmaceuticals

19 total trials

What the Registry Record Tells You About NCT00512317

The ClinicalTrials.gov registry entry for NCT00512317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ganaxolone is the first listed.

NCT00512317 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00512317 about?

NCT00512317 is a clinical study titled "Open-label Extension to Protocol 1042-0600". To allow open-label extension to patients who have completed Protocol 1042-0600.

What is the current status of trial NCT00512317?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2007-06. Estimated completion is 2013-09.

What interventions are being tested in trial NCT00512317?

The interventions under investigation include: ganaxolone (DRUG).

Who is sponsoring clinical trial NCT00512317?

This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.